Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 tofacitinib induction and maintenance study in pediatric ulcerative colitis
MOH_2021-10-12_010311Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Pfizer. Started Sep 2021; status: recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2021-10-12_010311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-12_010311.